Title: Glioblastoma Therapy with Substance P labelled with Bismuth-213
Authors: KROLICKI LeszekKUNIKOWSKA JolantaKOZIARA HMORGENSTERN AlfredBRUCHERTSEIFER FrankJAKUCINSKI MPAWLAK DariuszMIKOŁAJCZAK RenataKROLICKI BBARSZCZ Slawomir
Citation: World Journal of Nuclear Medicine vol. 12 no. Supplement 1 p. 22-23
Publisher: Medknow
Publication Year: 2013
JRC N°: JRC79497
ISSN: 1450-1147
URI: http://www.journalonweb.com/wjnm
http://publications.jrc.ec.europa.eu/repository/handle/JRC79497
Type: Articles in periodicals and books
Abstract: Gliomas are the most frequent primary brain tumors in adult patients. The most malignant of them – glioblastoma multiforme (GBM), is characterized by the worst prognosis with a median survival of 15 months. The infiltrating character of the tumor, molecular heterogeneity, as well as the protective effects of blood-brain barrier are the main causes of insufficient front line treatments (surgery, radio and chemotherapy); 90% of patients have a recurrence at the original tumor location. Therefore a new type of treatment strategies is urgently needed. Because the majority of recurrences occur within 2 cm of the resection margin, local therapies are currently under investigation. Riva P et al. in 1995 have proposed local treatment of malignant gliomas (1). This method allows for a higher concentration of drug into the tumor and omitting the blood-brain barrier. This method is also suitable for local administration of radiopharmaceuticals. Different types of biologically active ligands and radioisotopes were used.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.